As a chronic and relapsing disease, obesity negatively impacts the health of men 
to a greater extent than that of women, with a higher risk of cardiovascular 
disease. Since lifestyle modifications alone are often challenging and limited 
for the maintenance of weight reduction, pharmacotherapy should be considered in 
a timely manner for obese men or overweight patients with weight-related 
comorbidities. Recent advances in anti-obesity drugs have enabled the potential 
of achieving clinically significant weight loss. Increasing evidence has shown 
that behavior-based interventions with one of these medications can result in 
greater weight loss than that elicited by usual care conditions. Data from most 
recent meta-analyses showed that the overall placebo-subtracted weight reduction 
(%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% 
to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), 
naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). However, 
they have a high cost and may cause adverse outcomes depending on the 
individual. Very recently, on February 13, 2020, the US Food and Drug 
Administration requested withdrawal of lorcaserin from the market because a 
safety clinical trial showed an increased occurrence of cancer. Therefore the 
decision to initiate drug therapy in obese individuals should be made after the 
benefits and risks are considered. Thereafter, treatment should be tailored to 
specific patient subpopulations depending on their chronic conditions, 
comorbidities, and preferences. Herein, we provide an overview of the latest 
developments in weight loss medications, which may serve as one of the 
strategies for long-term obesity control.